Provided by Tiger Trade Technology Pte. Ltd.

ProMIS Neurosciences Inc

9.61
+0.46005.03%
Post-market: 9.610.00000.00%19:30 EDT
Volume:18.85K
Turnover:183.53K
Market Cap:86.18M
PE:-0.76
High:10.15
Open:9.06
Low:9.06
Close:9.15
52wk High:27.40
52wk Low:6.27
Shares:8.97M
Float Shares:4.39M
Volume Ratio:0.62
T/O Rate:0.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.6200
EPS(LYR):-22.6100
ROE:-172.30%
ROA:-81.06%
PB:1.74
PE(LYR):-0.43

Loading ...

ProMIS Neurosciences Files Form 3 Initial Beneficial Ownership Statement for Chief Commercial Officer Ivana Rubino

Reuters
·
Oct 07

ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.d., as Chief Commercial Officer

THOMSON REUTERS
·
Oct 06

Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug

GlobeNewswire
·
Oct 02

ProMIS Neurosciences to Present at Chardan Annual Healthcare Conference Panel on Neurodegenerative Diseases

Reuters
·
Sep 30

ProMIS Neurosciences to Present at Cantor Global Healthcare Conference

Reuters
·
Sep 01

ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September

GlobeNewswire
·
Sep 01

ProMIS Neurosciences price target lowered to $29 from $30 at Roth Capital

TIPRANKS
·
Aug 21

ProMIS Neurosciences Price Target Raised to $100.00/Share from $69.00 by Guggenheim

Dow Jones
·
Aug 14

Guggenheim Reaffirms Their Buy Rating on ProMIS Neurosciences (PMN)

TIPRANKS
·
Aug 14

Annovis Bio Q2 Loss Widens as R&D Costs Rise

Reuters
·
Aug 14

Analysts Are Bullish on These Healthcare Stocks: ProMIS Neurosciences (PMN), Ascendis Pharma (ASND)

TIPRANKS
·
Aug 14

ProMIS Neurosciences Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 14

ProMIS Neurosciences Q2 Net Loss Widens

Reuters
·
Aug 14

ProMIS Neurosciences Q2 EPS $(1.28) Beats $(1.38) Estimate

Benzinga Earnings
·
Aug 14

ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights

THOMSON REUTERS
·
Aug 14

ProMIS Neurosciences Q2 EPS USD -1.28

THOMSON REUTERS
·
Aug 14

ProMIS Neurosciences Inc Expected to Post a Loss of $1.38 a Share - Earnings Preview

Reuters
·
Aug 11

ProMIS Neurosciences Chief Development Officer Johanne Kaplan Acquires 2,280 Common Shares Worth $30,324

Reuters
·
Aug 08

ProMIS Neurosciences to Report Q2 Results, Host Investor Call and Webcast

Reuters
·
Aug 04

ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026

GlobeNewswire
·
Aug 04